Key TakeawaysJohnson & Johnson on Wednesday reported second-quarter earnings with sales topping estimates.However, profits fell short of projections thanks to one-time costs like legal fees and asset amortization.The company lifted its full-year sales guidance, while also lowering profit estimates. Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales. Sales of the company's pharmaceuticals an ...

2nd Quarter 2024 Results¹ 2nd Quarter 2024 Sales Worldwide increased ▲ Excluding acquisitions / divestitures on an operational basis Worldwide increased ▲ Diluted earnings per share Adjusted diluted earnings per share* Increased ▲ 10.2% Joaquin Duato Chairman & Chief Executive Officer Johnson & Johnson 66 Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth ...

Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.06%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.64 per share when it actually produced earnings of $2.71, delivering a surprise of 2.65%.Over ...

Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) SECOND QUARTER Percent Change | --- | --- | --- | --- | --- | --- | |---------------------------------------|---------|--------|-------|------------|----------| | Sales to customers by geographic area | 2024 | 2023 | Total | Operations | Currency | | U.S. | $12,569 | 11,657 | 7.8 % | 7.8 | — | | Europe | 5,214 | 5,131 | 1.6 | 3.4 | (1.8) | | Western Hemisphere excluding U.S. | 1,212 | 1,136 | 6.7 | 22.6 ...

Loading...Loading...Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.The stock is down 5.56% over the past year, -4.16% YTD.Let’s look at what the charts indicate for Johnson & Johnson stock and how the stock currently maps against Wall Street estimates.Johnson & Johnson Technical Setup Ahead Of Q2 Earnings Johnson & Johnson stock is exhibiting a strongly bullish trend, as its ...

Loading...Loading...Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro.Emergent BioSolutions Inc EBS, through its subsidiary Emergent Manufactu ...

GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively. J&J will likely ...

Johnson & Johnson (JNJ) will report its second-quarter 2024 earnings on Jul 17. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $22.38 billion and $2.71 per share, respectively. Earnings estimates for JNJ have declined from $10.64 per share to $10.50 per share for 2024 and from $10.92 per share to $10.86 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been ...

SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Got ...

They don't have the most exciting businesses, but they have a lot to offer nonetheless.Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the changing trends in the sector tend to last. That describes Johnson & Johnson (JNJ 0.12%) and Medtronic (MDT -0.15%) well. Both are among the largest healthcare companies in the world, have proven innovative abilities, and have ...